At least 11 biotechs gained or lost 10% or more last week after presenting at the American Society of Clinical Oncology meeting in Chicago. Advaxis Inc. (NASDAQ:ADXS) led the gainers, with a 19% gain on the week after reporting long-term survival data for ADXS-HPV (ADXS11-001) in recurrent cervical cancer. ADXS-HPV is a live Listeria monocytogenes-based immunotherapy expressing HPV type 16 E7.

Ignyta Inc. (NASDAQ:RXDX) and Seattle Genetics Inc. (NASDAQ:SGEN) both posted significant gains on interim Phase I data. Ignyta presented data on RXDX-101, an oral inhibitor of c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), neurotrophic tyrosine kinase receptor 1 (NTRK1; TrkA) and anaplastic lymphoma kinase (ALK). Seattle Genetics presented data on SGN-CD19A, an antibody-drug conjugate (ADC) composed of an anti-CD19 mAb and monomethyl auristatin F (MMAF).